



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**

(13) **A1**


(86) Date de dépôt PCT/PCT Filing Date: 2019/11/20
(87) Date publication PCT/PCT Publication Date: 2020/06/18
(85) Entrée phase nationale/National Entry: 2021/03/01
(86) N° demande PCT/PCT Application No.: KR 2019/015902
(87) N° publication PCT/PCT Publication No.: 2020/122450
(30) Priorités/Priorities: 2018/12/10 (KR10-2018-0158623);
2019/10/23 (KR10-2019-0132138)

(51) Cl.Int./Int.Cl. *C12Q 1/689* (2018.01),
A23L 33/135 (2016.01), *A61K 35/74* (2015.01),
A61K 8/99 (2017.01), *A61P 1/16* (2006.01),
A61P 13/12 (2006.01), *A61P 17/00* (2006.01),
A61P 3/10 (2006.01), *A61P 35/00* (2006.01),
A61Q 19/00 (2006.01)
(71) Demandeur/Applicant:
MD HEALTHCARE INC., KR
(72) Inventeur/Inventor:
KIM, YOON-KEUN, KR
(74) Agent: BROUILLETTE LEGAL INC.

(54) Titre : NANOVESICULES DERIVEES DE BACTERIES DU GENRE SPHINGOMONAS ET LEURS UTILISATIONS
(54) Title: NANO-VESICLES DERIVED FROM GENUS SPHINGOMONAS BACTERIA AND USE THEREOF

[圖17]

Brain-specific Distribution



(57) **Abrégé/Abstract:**

The present invention relates to vesicles derived from bacteria of the genus *Sphingomonas*, and uses of same. The present inventors confirmed through experiments that compared to a normal individual, there is a significant decrease of said vesicles in

(57) Abrégé(suite)/Abstract(continued):

clinical samples of patients with cirrhosis, liver cancer, myocardial infarction, kidney failure, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and that an administration of vesicles isolated from the strains significantly suppresses the secretion of inflammatory mediators by pathogenic vesicles, such as vesicles derived from *E. coli*, wherein said vesicles, when orally administered, are distributed to brain tissues. Accordingly, the vesicles derived from bacteria of the genus *Sphingomonas* according to the present invention have promising uses in: developing detection methods for cirrhosis, liver cancer, myocardial infarction, kidney failure, diabetes, brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis; compositions for preventing, alleviating or treating said diseases; and drug carriers enabling the delivery of drugs to the brain.

【ABSTRACT】

Vesicles derived from bacteria belonging to the genus *Sphingomonas* and a use thereof. Vesicles were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to normal individuals, and when vesicles isolated from the strain were administered, the secretion of inflammatory mediators by pathogenic vesicles such as *E. coli*-derived vesicles was remarkably suppressed. When the vesicles were orally administered, they were distributed in the brain tissue. Vesicles derived from bacteria belonging to the genus *Sphingomonas* are expected to be usefully used for the purpose of developing a method of diagnosing hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, a composition for preventing, alleviating, or treating the diseases, and a drug carrier which delivers a drug to the brain.

【DESCRIPTION】**【Invention Title】**

NANO-VESICLES DERIVED FROM GENUS SPHINGOMONAS BACTERIA
AND USE THEREOF

5

【Technical Field】

The present invention relates to nanovesicles derived from bacteria belonging to the genus *Sphingomonas* and a use thereof, and more particularly to a method for diagnosing hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and the like using nanovesicles derived from bacteria belonging to the genus *Sphingomonas*, a composition for preventing, alleviating, or treating the disease, comprising the vesicles, a composition for delivering a drug for treating a brain disease, comprising the vesicles, and the like.

This application claims priority to and the benefit of Korean Patent Application Nos. 10-2018-0158623 and 10-2019-0132138 filed in the Korean Intellectual Property Office on December 10, 2018 and October 23, 2019, respectively, and all the contents disclosed in the specifications and drawings of those applications are incorporated in this application.

20

【Background Art】

Since the beginning of the 21st century, acute infectious diseases recognized as epidemic diseases in the past have become less important, whereas chronic diseases accompanied by immune dysfunction caused by disharmony between

humans and microbiomes have changed disease patterns as main diseases that determine the quality of life and the human lifespan. As an intractable chronic disease in the 21st century, cancer, cardiovascular diseases, allergic-chronic lung diseases, metabolic diseases, and neuropsychiatric diseases have become a big
 5 problem for public health in the country as main diseases that determine the human lifespan and the quality of life.

It is known that the number of microorganisms coexisting in the human body has reached 100 trillion, which is 10 times more than the number of human cells, and the number of microorganism genes is more than 100 times the number of human
 10 genes. A microbiota or microbiome refers to a microbial community including bacteria, archaea and eukarya present in a given habitat.

Bacteria coexisting in our body and bacteria present in the ambient environment secrete nanometer-sized vesicles in order to exchange information on genes, low molecular compounds, proteins, and the like with other cells. The
 15 mucosa forms a physical defense membrane through which particles having a size of 200 nanometers (nm) or more cannot pass, so that bacteria coexisting in the mucosa cannot pass through the mucosa, but vesicles derived from bacteria have a size of 100 nanometers or less and are absorbed into our bodies after relatively freely passing through epithelial cells via the mucosa. Bacteria-derived vesicles that are
 20 locally secreted from bacteria are absorbed via epithelial cells of the mucous membrane to thereby induce a local inflammatory response, and the vesicles having passed through the epithelial cells are systematically absorbed via lymphatic vessels and thereby distributed in respective organs, and immune and inflammatory responses are regulated in the organs in which the vesicles are distributed. For
 25 example, vesicles derived from pathogenic Gram-negative bacteria such as

Escherichia coli locally induce inflammatory response and cancer, and promote systemic inflammatory responses and blood coagulation through vascular endothelial cell inflammatory responses when absorbed via the blood vessels. In addition, such vesicles are absorbed into muscle cells on which insulin acts, and the like to cause

5 insulin resistance and diabetes. In contrast, vesicles derived from beneficial bacteria may regulate diseases by regulating immune functions and metabolic dysfunctions by pathogenic vesicles.

As immune responses to factors such as bacteria-derived vesicles, Th17 immune responses characterized by the secretion of the interleukin (hereinafter, IL)-

10 17 cytokine occur, and IL-6 is secreted from epithelial cells and immune cells when exposed to bacteria-derived vesicles, thereby inducing Th17 immune responses. Inflammation caused by the Th17 immune response is characterized by neutrophil infiltration, and during the process by which inflammation occurs, tumor necrosis factor-alpha (hereinafter, TNF- α) secreted from inflammatory cells such as

15 neutrophils and macrophages plays an important role in inflammation and oncogenesis.

Bacteria belonging to the genus *Sphingomonas* are aerobic Gram-negative bacteria that widely inhabit nature such as water, soil, and plant roots, and other Gram-negative bacteria have a lipopolysaccharide (LPS) in the outer cell membrane,

20 whereas bacteria belonging to the genus *Sphingomonas* have a glycosphingolipid (GSL) in the cell outer membrane. Twenty species of the genus *Sphingomonas* are known, and among them, *Sphingomonas paucimobilis* has been reported to cause hospital acquired infections in humans. However, no case has yet been reported in which vesicles derived from bacteria belonging to the genus *Sphingomonas* including

the aforementioned bacteria are applied to the diagnosis and treatment of an incurable disease such as cancer, a cardiovascular disease, and atopic dermatitis.

Thus, in the present invention, it was confirmed that a disease could be diagnosed by confirming that vesicles derived from bacteria belonging to the genus *Sphingomonas* were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, and atopic dermatitis compared to normal individuals. Further, as a result of isolating vesicles from *Sphingomonas paucimobilis* and *Sphingomonas koreensis* belonging to genus *Sphingomonas* bacteria and analyzing characteristics thereof, it was confirmed that the vesicles could be used as a composition for preventing or treating a disease such as hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis. Further, it was confirmed that when the vesicles were orally administered, a drug could be delivered to the brain.

15

【Disclosure】

【Technical Problem】

To address the above-described problems, as a result of having conducted intensive research, the inventors of the present invention confirmed through metagenomic analysis that the content of vesicles derived from bacteria belonging to the genus *Sphingomonas* was significantly reduced in samples derived from patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, compared to normal individuals. It was also confirmed that, when

isolating vesicles from *Sphingomonas paucimobilis* and *Sphingomonas koreensis*, which is a bacterium belonging to the genus *Sphingomonas* and treating macrophages therewith, the secretion of IL-6 and TNF- α by pathogenic vesicles was significantly inhibited, thus completing the present invention based on these findings.

5 Thus, an object of the present invention is to provide a method of diagnosing one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, or a method of providing information for diagnosis.

10 Further, another object of the present invention is to provide a composition for preventing, alleviating or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, comprising bacteria belonging to the genus
15 *Sphingomonas*-derived vesicles as an active ingredient.

In addition, still another object of the present invention is to provide a composition for delivering a drug for treating a brain disease, comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

20 However, a technical problem to be achieved by the present invention is not limited to the aforementioned problems, and the other problems that are not mentioned may be clearly understood by a person skilled in the art from the following description.

【Technical Solution】

25 To achieve the object of the present invention as described above, the present

invention provides a method of providing information for diagnosing one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, the method
 5 comprising the following steps:

(a) extracting DNAs from vesicles isolated from samples of a normal individual and a subject;

(b) performing polymerase chain reaction (PCR) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain
 10 each PCR product; and

(c) determining a case in which a content of vesicles derived from bacteria belonging to the genus *Sphingomonas* is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain
 15 tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, through quantitative analysis of the PCR product.

In addition, the present invention provides a method of diagnosing one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive
 20 impairment, dementia, depression, autism, and atopic dermatitis, the method comprising the following steps:

(a) extracting DNAs from vesicles isolated from samples of a normal individual and a subject;

(b) performing polymerase chain reaction (PCR) on the extracted DNA using
 25 a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain

each PCR product; and

(c) determining a case in which a content of vesicles derived from bacteria belonging to the genus *Sphingomonas* is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of hepatic
 5 cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, through quantitative analysis of the PCR product.

As an exemplary embodiment of the present invention, the sample in Step (a) may be blood or urine.

10 As another embodiment of the present invention, the primer pair in Step (b) may be a primer pair comprising base sequences represented by SEQ ID Nos. 1 and 2.

Further, the present invention provides a composition for preventing, alleviating, or treating one or more diseases selected from the group consisting of
 15 hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

The composition may comprise a pharmaceutical composition, a food
 20 composition, and a cosmetic composition.

Furthermore, the present invention provides a method of preventing or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild
 cognitive impairment, dementia, depression, autism, and atopic dermatitis, the
 25 method comprising a step of administering a composition comprising vesicles

derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient to a subject.

Further, the present invention provides a use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for preventing or treating one or more diseases
5 selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

Further, the present invention provides a use of a composition comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active
10 ingredient for preventing or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

In addition, the present invention provides a use of vesicles derived from
15 bacteria belonging to the genus *Sphingomonas* for producing a medicine used for one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

Furthermore, the present invention provides a drug carrier composition which
20 delivers a drug to the brain (or a composition for delivering a drug for treating a brain disease), comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

Further, the present invention provides a method of delivering a drug for treating a brain disease, the method comprising administering, to a subject, a
25 composition comprising bacteria belonging to the genus *Sphingomonas*-derived

vesicles in which a drug for treating a target brain disease is loaded as an active ingredient.

In addition, the present invention provides a use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for delivering a drug for treating a
5 brain disease.

As an exemplary embodiment of the present invention, the vesicles may have an average diameter of 10 to 200 nm.

As another exemplary embodiment of the present invention, the vesicles may be secreted naturally or artificially from bacteria belonging to the genus
10 *Sphingomonas*.

As still another embodiment of the present invention, the vesicles may be secreted by performing a method such as heat treatment and pressure treatment on the bacteria.

As yet another embodiment of the present invention, the vesicles derived
15 from bacteria belonging to the genus *Sphingomonas* may be secreted from *Sphingomonas paucimobilis*.

As yet another embodiment of the present invention, the vesicles derived from bacteria belonging to the genus *Sphingomonas* may be secreted from
20 *Sphingomonas koreensis*.

【Advantageous Effects】

The present inventors confirmed that bacteria are not absorbed into the body, but vesicles derived from bacteria are absorbed into the body through epithelial cells, systemically distributed, and excreted from the body through the kidneys, liver, and
25 lungs, and that through a metagenomic analysis of vesicles derived from bacteria

present in the blood of a patient, vesicles derived from bacteria belonging to a genus *Sphingomonas* present in the blood or urine of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis had been

5 significantly decreased as compared to those in normal individual. Further, it was observed that when genus *Sphingomonas* bacteria *Sphingomonas paucimobilis* and *Sphingomonas koreensis* were cultured ex vivo and vesicles were isolated and administered to inflammatory cells ex vivo, the secretion of inflammatory mediators by pathogenic vesicles was significantly suppressed. In addition, it was observed

10 that when *Sphingomonas paucimobilis* vesicles were orally administered, the vesicles were delivered to the brain. Thus, vesicles derived from bacteria belonging to the genus *Sphingomonas* according to the present invention can be used as a method of diagnosing hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and

15 atopic dermatitis, and as a composition for preventing, alleviating, or treating the diseases, such as a cosmetic, a food, or a drug, and furthermore can be expected to be usefully used as a drug carrier for delivering the drug to the brain.

【Description of Drawings】

20 FIG. 1A is a series of photographs capturing distribution patterns of bacteria and bacteria-derived vesicles (EV) by time after the bacteria and the vesicles derived from bacteria were orally administered to mice, and FIG. 1B is a result of evaluating the in vivo distribution patterns of the bacteria and the vesicles by harvesting blood, kidneys, liver, and various organs at 12 hours after orally administering the bacteria

25 and the vesicles.

FIG. 2 is a view of evaluating whether bacteria and bacteria-derived vesicles (EV) are infiltrated into intestinal mucosal epithelial cells after administering the bacteria and bacteria-derived vesicles to the intestine of a mouse (Lu, gut lumen; LP, gut lamina propria).

5 FIG. 3 is a result of comparing the distributions of vesicles derived from bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of hepatic cirrhosis patients, liver cancer patients and a normal individuals.

10 FIG. 4 is a result of comparing the distributions of vesicles derived from bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of myocardial infarction patients and a normal individuals.

15 FIG. 5 is a result of comparing the distributions of vesicles derived from bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of renal insufficiency patients and a normal individuals.

20 FIG. 6 is a result of comparing the distributions of vesicles derived from bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of diabetes patients and a normal individuals.

 FIG. 7 is a result of comparing the distributions of vesicles derived from bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of brain tumors patients and a normal individuals.

25 FIG. 8 is a result of comparing the distributions of vesicles derived from

bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of mild cognitive impairment patients, Alzheimer's dementia patients and a normal individuals.

FIG. 9 is a result of comparing the distributions of vesicles derived from
5 bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of bacteria-derived vesicles present in the blood of depression patients and a normal individuals.

FIG. 10 is a result of comparing the distributions of vesicles derived from
bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of
10 bacteria-derived vesicles present in the urine of autism patients and a normal individuals.

FIG. 11 is a result of comparing the distributions of vesicles derived from
bacteria belonging to the genus *Sphingomonas* after metagenomic analysis of
bacteria-derived vesicles present in the blood and urine of atopic dermatitis patients
15 and a normal individuals.

FIG. 12 is a result of evaluating apoptosis by treating microphages (Raw264.7 cells) with *Sphingomonas paucimobilis*-derived vesicles in order to evaluate the apoptotic effects of *Sphingomonas paucimobilis*-derived vesicles (EV, extracellular vesicle).

20 FIGS. 13A and 13B are results of comparing the secretion level of inflammatory mediators with that of *E. coli* EV which is a pathogenic vesicle by treating macrophages (Raw264.7 cells) with *Sphingomonas paucimobilis*-derived vesicles in order to evaluate the inflammation induction effects of *Sphingomonas paucimobilis*-derived vesicles, FIG. 13A compares the secretion levels of IL-6, and
25 FIG. 13B compares the secretion levels of TNF- α (EV: extracellular vesicle).

FIGS. 14A and 14B are results of evaluating effects of *E. coli* EV on the secretion of inflammatory mediators by pretreatment with *Sphingomonas paucimobilis*-derived vesicles prior to treatment with *E. coli* EV which is a pathogenic vesicle in order to evaluate the anti-inflammatory effects of

5 *Sphingomonas paucimobilis*-derived vesicles, FIG. 14A compares the secretion levels of IL-6, and FIG. 14B compares the secretion levels of TNF- α (SPC101, *Sphingomonas paucimobilis* EV; EV, extracellular vesicle).

FIGS. 15A and 15B are results of evaluating effects of *E. coli* EV on the secretion of inflammatory mediators by pretreatment with *Sphingomonas koreensis*-

10 derived vesicles prior to treatment with *E. coli* EV which is a pathogenic vesicle in order to evaluate the anti-inflammatory effects of *Sphingomonas koreensis*-derived vesicles, FIG. 15A compares the secretion levels of IL-6, and FIG. 15B compares the secretion levels of TNF- α (SPC102, *Sphingomonas koreensis* EV; EV, extracellular vesicle).

15 FIG. 16 is a series of photographs capturing distribution patterns of *Sphingomonas paucimobilis*-derived vesicles by time after the *Sphingomonas paucimobilis*-derived vesicles were orally administered to mice.

FIG. 17 is a series of views distribution patterns of *Sphingomonas paucimobilis*-derived vesicles in brain tissues by time after the *Sphingomonas*

20 *paucimobilis*-derived vesicles were orally administered to mice.

【Modes of the Invention】

The present invention relates to vesicles derived from bacteria belonging to the genus *Sphingomonas* and a use thereof.

The present inventors confirmed through metagenomic analysis that the content of vesicles derived from bacteria belonging to the genus *Sphingomonas* was remarkably reduced in samples derived from patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild
 5 cognitive impairment, dementia, depression, autism, and atopic dermatitis as compared to that of the samples derived from normal individuals, thereby completing the present invention based on this.

Thus, the present invention provides a method of diagnosing one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer,
 10 myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, or a method of providing information for diagnosis thereof, the method comprising the following steps:

(a) extracting DNAs from vesicles isolated from samples of a normal
 15 individual and a subject;

(b) performing polymerase chain reaction (PCR) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and

(c) determining a case in which a content of vesicles derived from bacteria
 20 belonging to the genus *Sphingomonas* is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, through quantitative analysis of the PCR product.

25 The term “diagnosis” as used herein refers to determination of a condition of

a disease of a patient over all aspects, in a broad sense. The contents of the determination are the disease entity, the etiology, the pathogenesis, the severity, the detailed aspects of a disease, the presence and absence of complications, the prognosis, and the like. The diagnosis in the present invention means determining
 5 whether hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, or atopic dermatitis occur, the level of the disease, and the like.

The term “nanovesicle” or “vesicle” as used herein refers to a structure consisting of a nano-sized membrane secreted from various bacteria. Vesicles
 10 derived from gram-negative bacteria or outer membrane vesicles (OMVs) have endotoxins (lipopolysaccharides) or glycosphingolipid, toxic proteins, and bacterial DNA and RNA, and vesicles derived from gram-positive bacteria also have peptidoglycan and lipoteichoic acid which are cell wall components of bacteria in addition to proteins and nucleic acids. In the present invention, nanovesicles or
 15 vesicles are secreted naturally from bacteria belonging to the genus *Sphingomonas* or produced artificially by performing heat treatment, pressure treatment, or the like on the bacteria, and have an average diameter of 10 to 200 nm.

The term “metagenome” as used herein also refers to a microbiome, and refers to a total of genomes including all viruses, bacteria, fungi, and the like in an
 20 isolated region such as soil and an animal’s intestines, and is typically used as a concept of genomes explaining identification of a large number of microorganisms at one time by using a sequence analyzer in order to analyze uncultivated microorganisms. In particular, the metagenome does not refer to a genome of one species, but refers to a kind of mixed genome as a genome of all species of one
 25 environmental unit. The metagenome is, when one species is defined in the

development process of omics biology, a term derived from the viewpoint of making a complete species is made by various species interacting with each other as well as one kind of functionally existing species. Technically, the metagenome is an object of a technique to identify all species in one environment and investigate interactions and metabolism by analyzing all DNAs and RNAs regardless of species using a rapid sequence analysis method.

The vesicles may be isolated from a culturing solution comprising bacteria belonging to the genus *Sphingomonas* by using one or more methods selected from the group consisting of centrifugation, ultra-high speed centrifugation, high pressure treatment, extrusion, sonication, cell lysis, homogenization, freezing-thawing, electroporation, mechanical decomposition, chemical treatment, filtration by a filter, gel filtration chromatography, free-flow electrophoresis, and capillary electrophoresis. Further, a process such as washing for removing impurities and concentration of obtained vesicles may be further included.

In the present invention, the sample in Step (a) may be blood or urine, but is not limited thereto.

In the present invention, the primer pair in Step (b) may be a primer pair comprising base sequences represented by SEQ ID Nos. 1 and 2, but is not limited thereto.

As another aspect of the present invention, the present invention provides a composition for preventing, alleviating, or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

The composition comprises a pharmaceutical composition, a food composition, and a cosmetic composition.

As another aspect of the present invention, the present invention provides a method of preventing or treating one or more diseases selected from the group
 5 consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, the method comprising a step of administering a composition comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient to a subject.

10 As another aspect of the present invention, the present invention provides a use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for preventing or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic
 15 dermatitis.

As another aspect of the present invention, the present invention provides a use of a composition comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient for preventing or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer,
 20 myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

As another aspect of the present invention, the present invention provides a use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for producing a medicine used for one or more diseases selected from the group
 25 consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal

insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

As another aspect of the present invention, the present invention provides a method of delivering a drug for treating a brain disease, the method comprising
5 administering, to a subject, a composition comprising bacteria belonging to the genus *Sphingomonas*-derived vesicles in which a drug for treating a target brain disease is loaded as an active ingredient.

As another aspect of the present invention, the present invention provides a use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for
10 delivering a drug for treating a brain disease.

The term “prevention” as used herein refers to all actions that suppress hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and the like or delay the onset thereof via administration of the
15 composition according to the present invention.

The term “treatment” as used herein refers to all actions that alleviate or beneficially change symptoms of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and the like via administration of
20 composition according to the present invention.

The term “alleviation” used as used herein refers to all actions that at least reduce a parameter associated with a condition to be treated, for example, the degree of symptoms.

As used herein, the term "drug carrier" refers to all means or actions which load and deliver a drug in the composition according to the present invention in order to deliver the drug to a specific organ, tissue, cell, or organelle.

In one embodiment of the present invention, as a result of orally
5 administering bacteria and bacteria-derived vesicles to mice and observing *in vivo* absorption, distribution, and excretion patterns of the bacteria and the vesicles, it was confirmed that, while the bacteria were not absorbed via the intestinal mucous membrane, the bacteria-derived vesicles were absorbed within 5 minutes after administration and systemically distributed, and excreted via the kidneys, liver, and
10 the like (see Example 1).

In another exemplary embodiment of the present invention, it was evaluated whether bacteria and bacteria-derived vesicles directly administered to the intestines passed through the protective membrane of the mucosa, and it was confirmed that bacteria failed to pass through the protective membrane of the mucosa, whereas
15 bacteria-derived vesicles passed through the protective membrane of the mucosa. (See Example 2).

In still another exemplary embodiment of the present invention, a bacterial metagenomic analysis was performed using vesicles isolated from the blood or urine of patients with hepatic cirrhosis, liver cancer, myocardial infarction, renal
20 insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis and normal individuals who were matched in age and sex with the patients. As a result, it was confirmed that vesicles derived from bacteria belonging to the genus *Sphingomonas* were significantly decreased in clinical samples of patients with hepatic cirrhosis, liver cancer, myocardial
25 infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment,

dementia, depression, autism, and atopic dermatitis as compared to samples of normal individuals (see Examples 4 to 12).

In yet another exemplary embodiment of the present invention, inflammation induction effects of vesicles secreted from *Sphingomonas paucimobilis* and
 5 *Sphingomonas koreensis* strains were evaluated by culturing the strains, and as a result of comparing the secretion levels of inflammatory mediators by treating macrophages with the bacteria-derived vesicles at various concentrations, and then treating the macrophages with the *E. coli*-derived vesicles, which are pathogenic vesicles, the ability of inflammatory mediators to be secreted was remarkably
 10 reduced by the vesicles derived from bacteria belonging to the genus *Sphingomonas* as compared to the secretion of IL-6 and TNF- α by *E. coli*-derived vesicles (see Example 14).

In yet another exemplary embodiment of the present invention, anti-inflammatory effects of vesicles derived from *Sphingomonas paucimobilis* and
 15 *Sphingomonas koreensis* strains were evaluated, and as a result of evaluating the secretion of inflammatory mediators after treating macrophages with *Sphingomonas paucimobilis* and *Sphingomonas koreensis*-derived vesicles at various concentrations prior to treatment with *E. coli*-derived vesicles, which are pathogenic vesicles, it was confirmed the vesicles efficiently suppressed the secretion of IL-6 and TNF- α by
 20 inflammation-inducing *E. coli*-derived vesicles (see Examples 15 and 16).

In yet another exemplary embodiment of the present invention, it was confirmed that when *Sphingomonas paucimobilis*-derived vesicles were orally administered, the aforementioned vesicles were distributed in the stomach from the time point when 1 hour elapsed and distributed even in the small intestine and the
 25 large intestine from the time point when 3 hours elapsed, and it was confirmed that

the distribution in these organs was maintained until 72 hours. Furthermore, it was confirmed that fluorescence-labeled *Sphingomonas paucimobilis*-derived vesicles moved specifically to the brain from 3 hours, and were increased until 32 hours, and then gradually decreased until the time point when 72 hours elapsed (see Example 5 17).

The pharmaceutical composition of the present invention may include a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is typically used in formulation, and includes saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, a dextrose solution, a maltodextrin solution, glycerol, 10 ethanol, liposomes, and the like, but is not limited thereto, and may further include other typical additives such as an antioxidant and a buffer, if necessary. Further, the composition may be formulated into an injectable formulation, such as an aqueous solution, a suspension, and an emulsion, a pill, a capsule, a granule, or a tablet by additionally adding a diluent, a dispersant, a surfactant, a binder, a lubricant, and the 15 like. With regard to suitable pharmaceutically acceptable carriers and formulations, the composition may be preferably formulated according to each ingredient by using the method disclosed in the Remington's literature. The pharmaceutical composition of the present invention is not particularly limited in formulation, but may be formulated into an injection, an inhalant, an external preparation for skin, an 20 oral ingestion, or the like.

The pharmaceutical composition of the present invention may be orally administered or may be parenterally administered (for example, administered intravenously, subcutaneously, intradermally) according to the target method, and the administration dose may vary depending on the patient's condition and body weight, 25 severity of disease, drug form, and administration route and period, but may be

appropriately selected by those of ordinary skill in the art.

The pharmaceutical composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, the pharmaceutically effective amount refers to an amount sufficient to treat diseases at a reasonable benefit/risk ratio applicable to medical treatment, and an effective dosage level may be determined according to factors including types of diseases of patients, the severity of disease, the activity of drugs, sensitivity to drugs, administration time, administration route, excretion rate, treatment period, and simultaneously used drugs, and factors well known in other medical fields. The composition according to the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, may be administered sequentially or simultaneously with therapeutic agents in the related art, and may be administered in a single dose or multiple doses. It is important to administer the composition in a minimum amount that can obtain the maximum effect without any side effects, in consideration of all the aforementioned factors, and this may be easily determined by those of ordinary skill in the art.

Specifically, an effective amount of the pharmaceutical composition according to the present invention may vary depending on the age, sex, and body weight of a patient, and may be increased or decreased depending on the route of administration, severity of obesity, sex, body weight, age, and the like.

The food composition of the present invention includes a health functional food composition. The food composition according to the present invention may be used by adding an active ingredient as is to food or may be used together with other foods or food ingredients, but may be appropriately used according to a typical method. The mixed amount of the active ingredient may be suitably determined

depending on the purpose of use thereof (for prevention or alleviation). In general, when a food or beverage is prepared, the composition of the present invention is added in an amount of 15 wt% or less, preferably 10 wt% or less based on the raw materials. However, for long-term intake for the purpose of health and hygiene or
5 for the purpose of health control, the amount may be less than the above-mentioned range.

Other ingredients are not particularly limited, except that the food composition of the present invention contains the active ingredient as an essential ingredient at the indicated ratio, and the food composition of the present invention
10 may contain various flavorants, natural carbohydrates, and the like, like a typical beverage, as an additional ingredient. Examples of the above-described natural carbohydrate include common sugars such as monosaccharides, for example, glucose, fructose and the like; disaccharides, for example, maltose, sucrose and the like; and polysaccharides, for example, dextrin, cyclodextrin and the like, and sugar alcohols
15 such as xylitol, sorbitol, and erythritol. As the flavorant other than those described above, a natural flavorant (thaumatin, stevia extract (for example, rebaudioside A, glycyrrhizin and the like), and a synthetic flavorant (saccharin, aspartame and the like) may be advantageously used. The proportion of the natural carbohydrate may be appropriately determined by the choice of those of ordinary skill in the art.

20 The food composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, colorants and fillers (cheese, chocolate, and the like), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols,
25 carbonating agents used in a carbonated beverage, or the like, in addition to the

additives. These ingredients may be used either alone or in combinations thereof. The ratio of these additives may also be appropriately selected by those of ordinary skill in the art.

The cosmetic composition of the present invention may include not only
 5 vesicles derived from bacteria belonging to the genus *Sphingomonas*, but also ingredients commonly used in cosmetic compositions, and may include, for example, general adjuvants such as an antioxidant, a stabilizer, a solubilizing agent, vitamins, pigments, and herbs, and a carrier.

In addition, the composition of the present invention may further include, in
 10 addition to the vesicles derived from bacteria belonging to the genus *Sphingomonas*, a mixture of organic UV blocking agents that have long been used within a range that does not adversely affect a skin protective effect by reaction with vesicles derived from bacteria belonging to the genus *Sphingomonas*. The organic UV blocking agent may be one or more selected from the group consisting of glyceryl PABA,
 15 drometrizole trisiloxane, drometrizole, digalloyl trioleate, disodium phenyl dibenzimidazole tetrasulfonate, diethylhexyl butamido triazone, diethylamino hydroxy benzoyl hexyl benzoate, DEA-methoxycinnamate, a mixture of lawsone and dihydroxyacetone, methylenebis-benzotriazolyltetramethylbutylphenol, 4-
 methylbenzylidene camphor, menthyl anthranilate, benzophenone-3(oxybenzone),
 20 benzophenone-4, benzophenone-8(dioxybenzone), butylmethoxydibenzoylmethane, bisethylhexyloxyphenolmethoxyphenyltriazine, cinoxate, ethyldihydroxypropyl PABA, octocrylene, ethylhexyldimethyl PABA, ethylhexylmethoxycinnamate, ethylhexyl salicylate, ethylhexyl triazone, isoamyl-p-methoxycinnamate, polysilicon-
 15(dimethicodiethylbenzal malonate), terephthalylidene dicamphor sulfonic acid and
 25 salts thereof, TEA-salicylate, and para-aminobenzoic acid (PABA).

Examples of products to which the cosmetic composition of the present invention may be added include cosmetics such as astringents, skin softeners, nourishing toners, various creams, essences, packs, foundations, and the like, cleansings, face cleansers, soaps, treatments, beauty liquids, and the like. Particular
 5 preparations of the cosmetic composition of the present invention include a skin lotion, a skin softener, a skin toner, an astringent, a lotion, a milk lotion, a moisturizing lotion, a nourishing lotion, a massage cream, a nourishing cream, a moisturizing cream, a hand cream, an essence, a nourishing essence, a pack, a soap, a shampoo, a cleansing foam, a cleansing lotion, a cleansing cream, a body lotion, a
 10 body cleanser, an emulsion, a lipstick, a makeup base, a foundation, a press powder, a loose powder, an eye shadow, and the like.

Hereinafter, preferred Examples for helping the understanding of the present invention will be suggested. However, the following Examples are provided only to more easily understand the present invention, and the contents of the present
 15 invention are not limited by the following Examples.

[Examples]

Example 1. Analysis of in vivo Absorption, Distribution, and Excretion Patterns of Bacteria and Vesicles Derived from Bacteria

20 In order to evaluate whether bacteria and bacteria-derived vesicles were systemically absorbed through the gastrointestinal tract, an experiment was performed with the following method. First, a dose of 50 μg of each of fluorescence-labeled bacteria and bacteria-derived vesicles was orally administered to the stomach of a mouse, and fluorescence was measured after 0 minute, 5 minutes,
 25 3 hours, 6 hours, and 12 hours. As a result of observing the entire image of the

mouse, as illustrated in FIG. 1A, the bacteria were not systemically absorbed, but the vesicles derived from bacteria were systemically absorbed 5 minutes after administration, and fluorescence was strongly observed in the bladder 3 hours after administration, so that it could be seen that the vesicles were excreted to the urinary tract. Further, it could be seen that the vesicles were present in the body until 12 hours after administration(see FIG. 1A).

In order to evaluate the pattern in which the bacteria and the vesicles derived from the bacteria infiltrated into various organs after they were systemically absorbed, 50 μ g of bacteria and vesicles derived from bacteria labeled with fluorescence were administered in the same manner as described above, and then the blood, heart, lungs, liver, kidneys, spleen, fat, and muscle were collected 12 hours after administration. As a result of observing fluorescence in the collected tissues, as illustrated in FIG. 1B, it could be seen that the vesicles derived from bacteria were distributed in the blood, heart, lungs, liver, spleen, fat, muscle, and kidneys but the bacteria were not absorbed(see FIG. 1B).

Example 2. Evaluation of whether bacteria and bacteria-derived vesicles penetrate protective membrane of intestinal mucosa

In order to evaluate whether bacteria and bacteria-derived vesicles passed through the protective membrane of the mucosa to be infiltrated into tissue, after bacteria and bacteria-derived vesicles were directly administered to the intestines, infiltration into the intestinal tissue after passing through the protective membrane of the mucosa was evaluated by an immunohistochemistry method. In order to evaluate the presence of bacteria and vesicles in the mucosal tissue, antibodies against the bacteria and the vesicles were prepared, attached to a green fluorescent

protein (GFP) and used, and after staining with 4, 6-diamidino 2-phenylindole (DAPI), observed under a microscope.

As a result, it was confirmed that bacteria failed to pass through the protective membrane of the mucosa, whereas bacteria-derived vesicles passed through the mucosa and infiltrated into the intestinal tissue (see FIG. 2).

Example 3. Metagenomic Analysis of Vesicles Derived from Bacteria in Clinical Sample

After blood or urine was first put into a 10-ml tube and suspended matter was allowed to settle by a centrifuge (3,500 x g, 10 min, 4°C), only the supernatant was transferred to a new 10-ml tube. After bacteria and impurities were removed by using a 0.22-µm filter, they were transferred to a Centriprep tube (centrifugal filters 50 kD) and centrifuged at 1,500 x g and 4°C for 15 minutes, materials smaller than 50 kD were discarded, and the residue was concentrated to 10 ml. After bacteria and impurities were removed once again by using a 0.22-µm filter, the supernatant was discarded by using a ultra-high speed centrifugation at 150,000 x g and 4°C for 3 hours with a Type 90Ti rotor, and an aggregated pellet was dissolved in physiological saline (PBS).

Internal DNA was extracted out of the lipid by boiling 100 µl of the vesicles isolated by the above method at 100°C, and then cooled on ice for 5 minutes. And then, in order to remove the remaining suspended matter, the DNA was centrifuged at 10,000 x g and 4°C for 30 minutes, and only the supernatant was collected. And, the amount of DNA was quantified by using Nanodrop. Thereafter, in order to confirm whether the DNA derived from bacteria was present in the extracted DNA, PCR was performed with 16s rDNA primers shown in the following Table 1 and it

was confirmed that genes derived from bacteria were present in the extracted genes.

[Table 1]

primer		Sequence	SEQ ID No.
16S rDNA	16S_V3_F	5'-TCGTCGGCAGCGTCAGATGTGTATAAGA GACAGCCTACGGGNGGCWGCAG-3'	1
	16S_V4_R	5'-GTCTCGTGGGCTCGGAGATGTGTATAAG AGACAGGACTACHVGGGTATCTAATCC	2

The DNA extracted by the above method was amplified using the 16S rDNA primers, and then sequencing was performed (Illumina MiSeq sequencer), the results were output as a standard flowgram format (SFF) file, the SFF file was converted into a sequence file (.fasta) and a nucleotide quality score file using GS FLX software (v2.9), and then the reliability estimation for the reads was confirmed, and a portion in which the window (20 bps) average base call accuracy was less than 99% (Phred score<20) was removed. For the OTU (operational taxonomy unit) analysis, clustering was performed according to sequence similarity by using UCLUST and USEARCH, the genus, family, order, class, and phylum were clustered based on 94%, 90%, 85%, 80%, and 75% sequence similarity, respectively, classification was performed at the phylum, class, order, family, and genus levels of each OUT, and bacteria having a sequence similarity of 97% or more at the genus level were profiled by using the 16S RNA sequence database (108,453 sequences) of BLASTN and GreenGenes (QIIME).

Example 4. Metagenomic analysis of bacteria-derived vesicles in blood of patient with liver disease

After a metagenomic analysis was performed using the method of Example 3

on the blood from 97 patients with hepatic cirrhosis, 76 patients with liver cancer, and 171 normal individuals who were matched in age and sex by extracting genes from vesicles present in the blood, the distribution of vesicles derived from bacteria belonging to the genus *Sphingomonas* was evaluated. As a result, it was confirmed
 5 that vesicles derived from belonging to the genus *Sphingomonas* were significantly decreased in the blood from the patients with hepatic cirrhosis and liver cancer as compared to the blood from the normal individuals (see FIG. 3).

Example 5. Metagenomic analysis of bacteria-derived vesicles in blood of
 10 **patient with myocardial infarction**

After a metagenomic analysis was performed using the method of Example 3 on the blood from 69 patients with myocardial infarction and 159 normal individuals who were matched in age and sex by extracting genes from vesicles present in the blood, the distribution of vesicles derived from bacteria belonging to the genus
 15 *Sphingomonas* was evaluated. As a result, it was confirmed that vesicles derived from belonging to the genus *Sphingomonas* were significantly decreased in the blood from the patients with myocardial infarction as compared to the blood from the normal individuals (see FIG. 4).

Example 6. Metagenomic analysis of bacteria-derived vesicles in blood of
 20 **patient with renal insufficiency**

After a metagenomic analysis was performed using the method of Example 3 on the blood from 36 patients with renal insufficiency and 72 normal individuals who were matched in age and sex by extracting genes from vesicles present in the blood,
 25 the distribution of vesicles derived from bacteria belonging to the genus

Sphingomonas was evaluated. As a result, it was confirmed that vesicles derived from belonging to the genus *Sphingomonas* were significantly decreased in the blood from the patients with renal insufficiency as compared to the blood from the normal individuals (see FIG. 5).

5

Example 7. Metagenomic analysis of bacteria-derived vesicles in blood of patient with diabetes

After a metagenomic analysis was performed using the method of Example 3 on the blood from 81 patients with diabetes and 126 normal individuals who were matched in age and sex by extracting genes from vesicles present in the blood, the distribution of vesicles derived from bacteria belonging to the genus *Sphingomonas* was evaluated. As a result, it was confirmed that vesicles derived from belonging to the genus *Sphingomonas* were significantly decreased in the blood from the patients with diabetes as compared to the blood from the normal individuals (see FIG. 6).

15

Example 8. Metagenomic analysis of bacteria-derived vesicles in blood of patient with brain tumors

After a metagenomic analysis was performed using the method of Example 3 on the blood from 80 patients with brain tumors and 121 normal individuals who were matched in age and sex by extracting genes from vesicles present in the blood, the distribution of vesicles derived from bacteria belonging to the genus *Sphingomonas* was evaluated. As a result, it was confirmed that vesicles derived from belonging to the genus *Sphingomonas* were significantly decreased in the blood from the patients with brain tumors as compared to the blood from the normal

25

individuals (see FIG. 7).

Example 9. Metagenomic analysis of bacteria-derived vesicles in blood of patient with mild cognitive impairment and dementia

5 After a metagenomic analysis was performed using the method of Example 3
on the blood from 76 patients with mild cognitive impairment, 70 patients with
Alzheimer's dementia, and 146 normal individuals who were matched in age and sex
by extracting genes from vesicles present in the blood, the distribution of vesicles
derived from bacteria belonging to the genus *Sphingomonas* was evaluated. As a
10 result, it was confirmed that vesicles derived from belonging to the genus
Sphingomonas were significantly decreased in the blood from the patients with mild
cognitive impairment and Alzheimer's dementia as compared to the blood from the
normal individuals (see FIG. 8).

15 **Example 10. Metagenomic analysis of bacteria-derived vesicles in blood of patient with depression**

After a metagenomic analysis was performed using the method of Example 3
on the blood from 70 patients with depression and 140 normal individuals who were
matched in age and sex by extracting genes from vesicles present in the blood, the
20 distribution of vesicles derived from bacteria belonging to the genus *Sphingomonas*
was evaluated. As a result, it was confirmed that vesicles derived from belonging
to the genus *Sphingomonas* were significantly decreased in the blood from the
patients with depression as compared to the blood from the normal individuals (see
FIG. 9).

Example 11. Metagenomic analysis of bacteria-derived vesicles in urine of patient with autism

After a metagenomic analysis was performed using the method of Example 3
 5 on the urine from 30 patients with autism and 40 normal individuals who were
 matched in age and sex by extracting genes from vesicles present in the urine, the
 distribution of vesicles derived from bacteria belonging to the genus *Sphingomonas*
 was evaluated. As a result, it was confirmed that vesicles derived from belonging
 to the genus *Sphingomonas* were significantly decreased in the urine from the
 10 patients with autism as compared to the urine from the normal individuals (see FIG.
 10).

Example 12. Metagenomic analysis of bacteria-derived vesicles in blood and urine of patient with atopic dermatitis

15 After a metagenomic analysis was performed using the method of Example 3
 on the blood and urine from 61 patients with atopic dermatitis and 52 normal
 individuals who were matched in age and sex by extracting genes from vesicles
 present in the blood and urine, the distribution of vesicles derived from bacteria
 belonging to the genus *Sphingomonas* was evaluated. As a result, it was confirmed
 20 that vesicles derived from belonging to the genus *Sphingomonas* were significantly
 decreased in the blood and urine from the patients with atopic dermatitis as compared
 to the blood and urine from the normal individuals (see FIG. 11).

Example 13. Isolation of Vesicles from *Sphingomonas paucimobilis* and

Sphingomonas koreensis Culturing Solution

Based on the above examples, a *Sphingomonas paucimobilis* and a *Sphingomonas koreensis* strain were cultured, and then vesicles were isolated therefrom and characteristics of the isolated vesicles were analyzed. The strains
 5 were cultured in a de Man-Rogosa and Sharpe (MRS) medium in an incubator at 37°C until the absorbance (OD 600) became 1.0 to 1.5, and then sub-cultured in a Luria-Bertani (LB) medium. Subsequently, a culture supernatant including the strain was recovered and centrifuged at 10,000 x g and 4 °C for 20 minutes, and then the strain was removed and filtered through a 0.22 µm filter. The filtered
 10 supernatant was concentrated to a volume of less than or equal to 50 ml through microfiltration by using a MasterFlex pump system (Cole-Parmer, US) with a 100 kDa Pellicon 2 Cassette filter membrane (Merck Millipore, US). The concentrated supernatant was filtered once again with a 0.22-µm filter. Thereafter, proteins were quantified by using a BCA assay, and the following experiments were performed on
 15 the obtained vesicles.

Example 14. Inflammation-inducing Effect of *Sphingomonas paucimobilis*-derived Vesicles

To examine an effect of *Sphingomonas paucimobilis*-derived vesicles
 20 (*Sphingomonas paucimobilis* EV, SPC101) on the secretion of inflammatory mediators (IL-6 and TNF-α) in inflammatory cells, Raw 264.7 cells, which is a mouse macrophage line, were treated with *Sphingomonas paucimobilis*-derived vesicles at various concentrations (0.1, 1, or 10 µg/ml), followed by apoptosis and ELISA.

More specifically, Raw 264.7 cells aliquoted at 5×10^4 cells/well into a 48-well cell culture plate were treated with *Sphingomonas paucimobilis*-derived vesicles at various concentrations, which were diluted with a DMEM (Dulbecos Modified Eagles Medium) serum-free medium, and the treated cells were cultured for 12 hours. Thereafter, apoptosis was measured by using EZ-CYTOX (Dogen, Korea), the cell culture solution was collected in a 1.5-ml tube and centrifuged at 3,000 g for 5 minutes, the supernatant was recovered and stored at -80°C , and then an ELISA analysis was performed.

For ELISA, a capture antibody was diluted with phosphate buffered saline (PBS) and 50 μl aliquots thereof were dispensed into a 96-well polystyrene plate in accordance with a working concentration, and then allowed to react at 4°C overnight. Subsequently, the sample was washed three times with 100 μl of a PBST (0.05% Tween-20-containing PBS) solution, and then an RD (1% bovine serum albumin (BSA)-containing PBS) solution was dispensed in 100 μl aliquots, followed by blocking at room temperature for 1 hour, and then the sample and a standard were dispensed in 50 μl aliquots in accordance with concentration and allowed to react at room temperature for 2 hours. Then, the sample and the standard were washed three times with 100 μl of PBST, and then the detection antibody was diluted with RD, and the diluted solution was dispensed in 50 μl aliquots in accordance with a working concentration and allowed to react at room temperature for 2 hours. Thereafter, the sample and the standard were washed three times with 100 μl of PBST, and then streptavidin-horseradish peroxidase (HRP) (R&D Systems, USA) was diluted in RD to 1/40, and the diluted solution was dispensed in 50 μl aliquots and allowed to react at room temperature for 20 minutes.

Lastly, the sample and the standard were washed three times with 100 μl of

PBST, and then a 3,3',5,5'-tetramethylbenzidine (TMB) substrate (SurModics, USA) was dispensed in 50 µl aliquots, and then when color was developed after 5 minutes to 20 minutes, a 1M sulfuric acid solution was dispensed in 50 µl aliquots, thereby stopping the reaction, and absorbance at 450 nm was measured using a SpectraMax
 5 M3 microplate reader (Molecular Devices, USA).

As a result, as illustrated in FIG. 12, apoptosis due to the treatment with *Sphingomonas paucimobilis*-derived vesicles (SPC 101) was not observed (see FIG. 12). Further, as a result of evaluating the secretion pattern of inflammatory mediators in inflammatory cells, it was confirmed that the secretion of inflammatory
 10 mediators such as IL-6 (FIG. 13A) and TNF-α (FIG. 13B) was much reduced upon treatment with *Sphingomonas paucimobilis*-derived vesicles (SPC 101) compared to upon treatment with *E. coli*-derived vesicles (*E. coli* EV 1 µg/ml), which are a positive control (see FIGS. 13A and 13B).

15 **Example 15. Anti-inflammatory Effects of *Sphingomonas paucimobilis*-derived Vesicles**

In order to evaluate the anti-inflammatory effects of *Sphingomonas paucimobilis*-derived vesicles based on the result of Example 14, after mouse macrophage cell lines were pre-treated with *Sphingomonas paucimobilis*-derived
 20 vesicles (SPC 101) at various concentrations (0.1, 1, and 10 µg/ml) for 12 hours, the cell lines were treated with 1 µg/ml of *E. coli*-derived vesicles, which are a pathogenic factor, and then the secretion of inflammatory cytokines was measured by ELISA after 12 hours.

As a result, it was confirmed that upon pre-treatment with *Sphingomonas*
 25 *paucimobilis*-derived vesicles, the secretion of inflammatory mediators such as IL-6

(FIG. 14A) and TNF- α (FIG. 14B) induced in inflammatory cells by *E. coli*-derived vesicle stimulation was significantly suppressed (FIGS. 14A and 14B).

Example 16. Anti-inflammatory Effects of *Sphingomonas koreensis*-

5 derived Vesicles

In order to evaluate the anti-inflammatory effects of another bacteria belonging to the genus *Sphingomonas* based on the result of Example 14, after mouse macrophage cell lines were pre-treated with *Sphingomonas koreensis*-derived vesicles (SPC 102) at various concentrations (0.1, 1, and 10 $\mu\text{g/ml}$) for 12 hours, the
 10 cell lines were treated with 1 $\mu\text{g/ml}$ of *E. coli*-derived vesicles, which are a pathogenic factor, and then the secretion of inflammatory cytokines was measured by ELISA after 12 hours.

As a result, it was confirmed that upon pre-treatment with *Sphingomonas koreensis*-derived vesicles, the secretion of inflammatory mediators such as IL-6
 15 (FIG. 15A) and TNF- α (FIG. 15B) induced in inflammatory cells by *E. coli*-derived vesicle stimulation was significantly suppressed (FIGS. 15A and 15B).

Example 17. Distribution pattern of *Sphingomonas paucimobilis*-derived vesicles

20 In order to confirm the absorption and distribution in organs by time when *Sphingomonas paucimobilis*-derived vesicles were orally administered, an experiment was performed as follows. 10 μg of fluorescence-labeled *Sphingomonas paucimobilis*-derived vesicles was orally administered, and fluorescence was measured after 1, 3, 6, 32, 48, and 72 hours, respectively. As a
 25 result of observing the fluorescence of the entire mouse image, it was confirmed that

Sphingomonas paucimobilis-derived vesicles were distributed in the stomach from 1 hour after oral administration, and also distributed in the small intestine and the large intestine from 3 hours, and it was observed that the distribution in the organs was maintained until 72 hours (see FIG. 16).

5 In addition, it was confirmed that the fluorescence-labeled *Sphingomonas paucimobilis*-derived vesicles moved specifically to the brain from 3 hours, and it was confirmed that were the distribution degree of extracellular vesicles which had moved to the brain was increased until 32 hours, and then gradually decreased from 32 hours to 72 hours (see FIG. 17).

10 The above-described description of the present invention is provided for illustrative purposes, and those of ordinary skill in the art to which the present invention pertains will understand that the present invention can be easily modified into other specific forms without changing the technical spirit or essential features of the present invention. Therefore, it should be understood that the above-described
15 Examples are illustrative only in all aspects and are not restrictive.

【Industrial Applicability】

It was confirmed that vesicles derived from bacteria belonging to the genus *Sphingomonas* according to the present invention were absorbed *in vivo* through
20 epithelial cells, systemically distributed, and excreted *ex vivo* through the kidneys, the liver, and the lungs, and it was confirmed that the vesicles were significantly reduced in blood or urine of a patient with hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, a brain tumor, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, and the secretion of
25 inflammatory mediators by pathogenic vesicles can be significantly suppressed.

Therefore, the vesicles derived from bacteria belonging to the genus *Sphingomonas* according to the present invention are expected to have high industrial applicability value because the vesicles can be used as a method of diagnosing hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild
5 cognitive impairment, dementia, depression, autism, and atopic dermatitis, and as a composition for preventing, alleviating, or treating the diseases, such as a cosmetic, a food, or a drug, and furthermore can be usefully used as a drug carrier for delivering the drug to the brain.

【CLAIMS】**【Claim 1】**

A method of providing information for diagnosing one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, the method comprising the following steps:

- (a) extracting DNAs from vesicles isolated from samples of a normal individual and a subject;
- 10 (b) performing polymerase chain reaction (PCR) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain each PCR product; and
- (c) determining a case in which a content of vesicles derived from bacteria belonging to the genus *Sphingomonas* is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, through quantitative analysis of the PCR product.

20 **【Claim 2】**

The method of claim 1, wherein the sample in Step (a) is blood or urine.

【Claim 3】

A pharmaceutical composition for preventing or treating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, comprising vesicles derived
5 from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

【Claim 4】

The pharmaceutical composition of claim 3, wherein the vesicles have an average diameter of 10 to 200 nm.

10

【Claim 5】

The pharmaceutical composition of claim 3, wherein the vesicles are secreted naturally or artificially from bacteria belonging to the genus *Sphingomonas*.

15 **【Claim 6】**

The pharmaceutical composition of claim 3, wherein the vesicles derived from bacteria belonging to the genus *Sphingomonas* are secreted from *Sphingomonas paucimobilis*.

20 **【Claim 7】**

The pharmaceutical composition of claim 3, wherein the vesicles derived from bacteria belonging to the genus *Sphingomonas* are secreted from *Sphingomonas koreensis*.

【Claim 8】

A food composition for preventing or alleviating one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, 5 dementia, depression, autism, and atopic dermatitis, comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

【Claim 9】

The food composition of claim 8, wherein the vesicles have an average 10 diameter of 10 to 200 nm.

【Claim 10】

The food composition of claim 8, wherein the vesicles are secreted naturally or artificially from bacteria belonging to the genus *Sphingomonas*. 15

【Claim 11】

The food composition of claim 8, wherein the vesicles derived from bacteria belonging to the genus *Sphingomonas* are secreted from *Sphingomonas paucimobilis*.

20 【Claim 12】

The food composition of claim 8, wherein the vesicles derived from bacteria belonging to the genus *Sphingomonas* are secreted from *Sphingomonas koreensis*.

【Claim 13】

A cosmetic composition for preventing or alleviating atopic dermatitis, comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

5

【Claim 14】

A composition for delivering a drug for treating a brain disease, comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient.

10

【Claim 15】

The composition of claim 14, wherein the vesicles derived from bacteria belonging to the genus *Sphingomonas* are secreted from *Sphingomonas paucimobilis*.

15 **【Claim 16】**

The composition of claim 14, wherein the vesicles derived from bacteria belonging to the genus *Sphingomonas* are secreted from *Sphingomonas koreensis*.

【Claim 17】

20 A method of diagnosing one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, the method comprising the following steps:

(a) extracting DNAs from vesicles isolated from samples of a normal individual and a subject;

(b) performing polymerase chain reaction (PCR) on the extracted DNA using a pair of primers prepared based on a gene sequence present in 16S rDNA to obtain
5 each PCR product; and

(c) determining a case in which a content of vesicles derived from bacteria belonging to the genus *Sphingomonas* is lower than that of the normal individual sample, as one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain
10 tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, through quantitative analysis of the PCR product.

【Claim 18】

A method of preventing or treating one or more diseases selected from the
15 group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis, the method comprising a step of administering a composition comprising vesicles derived from bacteria belonging to the genus *Sphingomonas* as an active ingredient to a subject.

20

【Claim 19】

A use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for producing a medicine used for one or more diseases selected from the group consisting of hepatic cirrhosis, liver cancer, myocardial infarction, renal

insufficiency, diabetes, brain tumors, mild cognitive impairment, dementia, depression, autism, and atopic dermatitis.

【Claim 20】

- 5 A use of vesicles derived from bacteria belonging to the genus *Sphingomonas* for delivering a drug for treating a brain disease.

FIG. 1A




FIGURE
1/21

FIG. 1B






FIGURE
3/21
FIG. 2



**FIGURE
4/21**

FIG. 3


Blood EV



**FIGURE
5/21**

FIG. 4

Blood EV



**FIGURE
6/21**

FIG. 5

Blood EV





FIGURE
7/21


FIG. 6



**FIGURE
8/21**


FIG. 7

Blood EV




**FIGURE
9/21**

FIG. 8



**FIGURE
10/21**

FIG. 9



**FIGURE
11/21**

FIG. 10




FIGURE
12/21

FIG. 11






FIGURE
13/21

FIG. 12




**FIGURE
14/21****FIG. 13A**


SPC101: *Sphingomonas paucimobilis* EV

**FIGURE
15/21**


FIG. 13B



SPC101: *Sphingomonas paucimobilis* EV

**FIGURE
16/21****FIG. 14A**


SPC101: *Sphingomonas paucimobilis* EV

**FIGURE
17/21****FIG. 14B**


SPC101: *Sphingomonas paucimobilis* EV

FIGURE
18/21

FIG. 15A




SPC102: *Sphingomonas koreensis* EV

**FIGURE
19/21****FIG. 15B**

SPC102: *Sphingomonas koreensis* EV


**FIGURE
20/21**

FIG. 16



**FIGURE
21/21**

FIG. 17



[도17]

Brain-specific Distribution

